The identification of analogous “glycoimmune” T-cell checkpoints may thus be highly significant for the design and development of novel immunotherapies ( 2 ).
← all excerpts
The glycoimmune checkpoint receptor Siglec-7 interacts with T-cell ligands and regulates T-cell activation.
1
—
—